Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.45 |
| ▸ | HTT | P42858 | 4/20 | 0.45 |
| ▸ | GAA | P10253 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | CTRC | Q99895 | 1/20 | 0.43 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4698447 | 1.00 | MAPT (0.58) | MAPTSMN1; SMN2NPC1RAB9AALDH1A1 | |
| Hydrochloric Acid SCHEMBL17561003 | 0.98 | MAPT (0.56) | MAPTSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL4698394 | 0.89 | ALDH1A1 (0.53) | MAPTNPC1RAB9AALDH1A1POLB | |
| SCHEMBL4698601 | 0.87 | MAPT (0.50) | MAPTSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL4698606 | 0.87 | MAPT (0.50) | MAPTSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL7748696 | 0.86 | MAPT (0.55) | MAPTSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL7748700 | 0.86 | MAPT (0.55) | MAPTSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL31105723 | 0.86 | MAPT (0.55) | MAPTSMN1; SMN2NPC1RAB9AALDH1A1 | |
| Hydrochloric Acid SCHEMBL7747578 | 0.84 | MAPT (0.54) | MAPTSMN1; SMN2NPC1RAB9AALDH1A1 | |
| Hydrochloric Acid SCHEMBL7747576 | 0.84 | MAPT (0.54) | MAPTSMN1; SMN2NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1309544-B1 | COMPOUNDS ACTING AS MELANOCORTIN RECEPTOR LIGANDS | ACURE PHARMA AB (SE) | 2008-11-05 | — | — | EP | claimed |
| US-7153881-B2 | Compounds acting as melanocortin receptor ligands | ACURE PHARMA AB (SE) | 2006-12-26 | — | — | US | claimed |
| US-20220267258-A1 | ROBENIDINE ANALOGS AS POTENT ANTIMALARIALS AGAINST DRUG-RESISTANT PLASMODIUM FALCIPARUM | UNIV OREGON HEALTH & SCIENCE (US) | 2022-08-25 | — | — | US | disclosed |
| EP-3960729-A1 | COMPOUNDS AND METHODS OF TREATING INFECTIONS | Neoculi Pty Ltd (AU) | 2022-03-02 | — | — | EP | disclosed |
| EP-2991968-B1 | COMPOUNDS AND METHODS OF TREATING INFECTIONS | NEOCULI PTY LTD (AU) | 2021-11-10 | — | — | EP | disclosed |
| EP-3188722-B1 | METHODS FOR TREATING PROTOZOAN INFECTIONS | NEOCULI PTY LTD (AU) | 2021-08-04 | — | — | EP | disclosed |
| US-20200102287-A1 | METHODS FOR TREATING PROTOZOAN INFECTIONS | NEOCULI PTY LTD (AU) | 2020-04-02 | — | — | US | disclosed |
| US-20170291886-A1 | METHODS FOR TREATING PROTOZOAN INFECTIONS | NEOCULI PTY LTD (AU) | 2017-10-12 | — | — | US | disclosed |
| EP-1309544-B1 | COMPOUNDS ACTING AS MELANOCORTIN RECEPTOR LIGANDS | ACURE PHARMA AB (SE) | 2008-11-05 | — | — | EP | disclosed |
| US-7153881-B2 | Compounds acting as melanocortin receptor ligands | ACURE PHARMA AB (SE) | 2006-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170291886-A1 | METHODS FOR TREATING PROTOZOAN INFECTIONS | DPM1, ABCB11, PIGS | MAPT 3694/4885SMN1; SMN2 3002/4885NPC1 282/4885 |
| US-20200102287-A1 | METHODS FOR TREATING PROTOZOAN INFECTIONS | DPM1, ABCB11, PIGS | MAPT 3694/4885SMN1; SMN2 3002/4885NPC1 282/4885 |
| US-20220267258-A1 | ROBENIDINE ANALOGS AS POTENT ANTIMALARIALS AGAINST DRUG-RESISTANT PLASMODIUM FALCIPARUM | CYP3A43, CYP2C9, CYP3A4 | MAPT 277/4885SMN1; SMN2 4491/4885NPC1 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.